Cancer Advisor

Introduction: Why This Debate Went Viral In 2026, a high-profile medical dispute spread across X (Twitter) and Substack involving two physicians with opposing views on the use of benzimidazole drugs —notably fenbendazole (veterinary dewormer) and mebendazole (human antiparasitic) —as potential cancer treatments. Naturopathic physician Dr. Colleen Huber, from her Arizona clinic, warned against using mebendazole and fenbendazole for cancer, calling it a risky fad that damages essential cell structures. Former physician William Makis countered with mebendazole's history since 1971, FDA approval for children as young as one, and his experience treating over 9,000 patients—though unverified. While lab studies show anticancer promise by disrupting tumor growth like some chemotherapies, human evidence is limited, fenbendazole remains veterinary-only with liver risks, and experts recommend sticking to proven treatments under medical guidance. ( X.com ) ...

Introduction: Why VO₂ Peak Matters in Cancer VO₂ peak—also known as VO₂ max—is one of the strongest physiological indicators of overall health and survival risk. It measures how efficiently the body uses oxygen during maximal exertion and reflects the integrated function of the heart, lungs, blood, and muscles. In oncology, VO₂ peak has emerged as a powerful predictor of treatment tolerance, postoperative outcomes, and long-term survival across multiple cancer types. Rather than being a direct cancer biomarker, VO₂ peak acts as a systemic resilience marker , shaping how well the body withstands both disease and treatment stress. What Is VO₂ Peak? VO₂ peak represents the maximum oxygen uptake (mL/kg/min) during intense exercise. It reflects: Cardiovascular efficiency Pulmonary oxygen exchange Skeletal muscle mitochondrial function Metabolic flexibility Clinically, VO₂ peak is increasingly treated as a “vital sign of fitness” in cancer care and surgical risk assessment. VO₂ Peak and Ca...

Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...